Comprehensive medication guide to Mycophenolate Mofetil including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$5–$40 co-pay per month for generic on most commercial plans (Tier 2); brand-name CellCept co-pay $57.50–$87.50 with insurance; 84% of insurance plans cover mycophenolate mofetil.
Estimated Cash Pricing
$419 retail for 60 x 500 mg tablets at full price; as low as $22–$37 with SingleCare or GoodRx coupons for generic; $17+ for 250 mg capsules. Brand-name CellCept is significantly higher without a savings card.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Mycophenolate mofetil (brand name CellCept) is an immunosuppressant medication approved by the FDA in 1995. It belongs to a class of drugs called selective IMPDH inhibitors and is used to prevent the immune system from rejecting transplanted organs or attacking the body's own tissues in autoimmune disease. It is available as a generic from multiple manufacturers and as brand-name CellCept from Genentech (Roche).
Mycophenolate mofetil is FDA-approved for prevention of rejection in kidney, heart, and liver transplants in adults and children ≥3 months of age. It is also widely prescribed off-label for systemic lupus erythematosus (SLE), lupus nephritis, vasculitis, myasthenia gravis, systemic sclerosis, pemphigus vulgaris, IgA nephropathy, and inflammatory bowel disease.
For transplant recipients, mycophenolate mofetil is a cornerstone of long-term immunosuppression — typically used in combination with a calcineurin inhibitor (tacrolimus or cyclosporine) and a corticosteroid. Most patients who receive an organ transplant will take this medication indefinitely.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Mycophenolate mofetil is a prodrug that is rapidly converted in the body to its active form — mycophenolic acid (MPA). MPA is a potent, selective, and reversible inhibitor of the enzyme inosine monophosphate dehydrogenase (IMPDH), which is the rate-limiting enzyme in the de novo synthesis of guanosine nucleotides.
T and B lymphocytes — the immune cells responsible for attacking foreign tissue and mounting autoimmune responses — are uniquely dependent on this de novo guanosine synthesis pathway when they are activated. By blocking IMPDH, MPA selectively prevents lymphocytes from proliferating, suppresses antibody production by B cells, and inhibits the migration of immune cells to sites of inflammation or graft rejection.
Most other cell types can use an alternative 'salvage pathway' for guanosine, making them less sensitive to IMPDH inhibition. This selectivity for lymphocytes is what makes mycophenolate mofetil effective as an immunosuppressant with a more targeted mechanism than older drugs like azathioprine or cyclophosphamide.
250 mg — capsule
Standard form for transplant dosing; two capsules equals one 500 mg tablet dose
500 mg — tablet
Most commonly prescribed form; standard kidney transplant dose is 1 tablet (500mg) twice daily
200 mg/mL — oral suspension
Myhibbin ready-to-use liquid suspension for patients unable to swallow solid forms; FDA approved 2024
500 mg — IV infusion
Hospital use only; infused over at least 2 hours; used when oral form not feasible post-transplant
Mycophenolate mofetil has active supply disruptions affecting multiple generic manufacturers, earning it a findability score of 45 out of 100. The medication appears on the ASHP drug shortage list, with manufacturers including Mylan, Sandoz, Hikma, Accord, Ascend, and Teva all having reported supply constraints at various times. Delayed-release mycophenolate sodium tablets have also been in shortage from some generic manufacturers.
The shortage is characterized by inconsistent, geographically uneven availability — some pharmacies in your area may have it in stock while others do not. Brand-name CellCept (Genentech) has generally maintained better availability than generics. In 2023, the End Drug Shortages Alliance identified mycophenolate mofetil as one of five essential medications at greatest risk of supply disruption.
If you're having trouble finding mycophenolate mofetil in stock, medfinder can call pharmacies in your area to find which ones have your medication. You provide your medication, dose, and zip code, and medfinder texts you the results.
Mycophenolate mofetil is not a controlled substance, so there are no DEA-specific prescribing restrictions. However, due to its complexity, boxed warnings (including teratogenicity and increased infection/malignancy risk), and the specialized monitoring required, initiation is almost always performed by a specialist. The FDA label specifies that prescribers should be experienced in immunosuppressive therapy and transplant management.
Specialists who commonly initiate mycophenolate mofetil include:
Telehealth prescribing of mycophenolate mofetil is feasible for established patients with their regular specialist for refills and follow-up. New patient initiation typically requires an in-person visit for baseline laboratory evaluation (CBC, CMP, urinalysis) and physical examination. Transplant care should always involve an established transplant center.
No. Mycophenolate mofetil is not a controlled substance and has no DEA schedule. It has no abuse potential, addiction potential, or street value. It can be prescribed by any licensed healthcare provider with prescribing authority, transferred between pharmacies without special restrictions, and filled via mail-order pharmacy. Multiple refills can be prescribed at once.
Despite not being a controlled substance, mycophenolate mofetil does carry a FDA REMS (Risk Evaluation and Mitigation Strategy) program related to its teratogenicity — specifically, the significant risk of pregnancy loss and birth defects. Female patients of reproductive potential must receive counseling about contraception requirements before and during therapy.
Most patients experience some side effects, especially gastrointestinal symptoms early in treatment:
Know what you need? Skip the search.
Azathioprine (Imuran)
Purine antimetabolite with similar mechanism; most common alternative for transplant and autoimmune disease; requires TPMT testing before use
Mycophenolate Sodium (Myfortic)
Enteric-coated delayed-release formulation delivering the same active drug; may have better GI tolerability; Myfortic 720mg BID ≈ MMF 1g BID
Tacrolimus (Prograf)
Calcineurin inhibitor used in transplant regimens; often combined with MMF rather than substituted for it
Cyclophosphamide (Cytoxan)
Used for induction therapy in severe lupus nephritis and vasculitis; more toxic; generally not used for maintenance
Sirolimus (Rapamune)
mTOR inhibitor used in kidney transplant; alternative when calcineurin inhibitor toxicity is a concern
Prefer Mycophenolate Mofetil? We can find it.
Cyclosporine
moderateReduces MMF blood levels 30-50% by inhibiting enterohepatic recirculation; patients may need higher MMF doses
Cholestyramine / bile acid sequestrants
majorSignificantly reduces MMF levels by interrupting enterohepatic recirculation; avoid concurrent use
Azathioprine
majorTherapeutic duplication — DO NOT combine; causes severe additive myelosuppression
PPIs (esomeprazole, omeprazole, etc.)
moderateReduces MMF absorption by raising gastric pH; clinical significance varies; monitor
NSAIDs (ibuprofen, naproxen)
moderateCompete for renal tubular secretion; may increase MMF levels; use acetaminophen for pain relief instead
Acyclovir / Ganciclovir / Valacyclovir
moderateCompete for renal tubular secretion with MPAG metabolite; increases levels of both drugs; monitor carefully
Live vaccines
majorAvoid all live vaccines (MMR, varicella, live shingles, live flu nasal spray) during therapy; risk of serious vaccine-strain infection
Rifampin
moderateReduces MPA exposure significantly; may require dose adjustment; monitor for reduced immunosuppressive effect
Mycophenolate mofetil is a critical medication for hundreds of thousands of Americans — transplant recipients who depend on it to keep their organs, and autoimmune patients who depend on it to prevent disease flares. It is one of the most important immunosuppressants in modern medicine, with a well-established 30-year track record across multiple indications.
The most important things to know in 2026: the drug is experiencing active supply disruptions affecting multiple manufacturers, so proactive refill planning is essential; cost management tools like GoodRx, SingleCare, and the Genentech savings card can dramatically reduce out-of-pocket expense; and missing doses carries real clinical risk for both transplant and autoimmune patients.
If you're struggling to find mycophenolate mofetil in stock at your pharmacy, medfinder can help. Provide your medication, dose, and location, and medfinder will call pharmacies near you to find which ones have your prescription ready to fill — then text you the results. This service is particularly valuable for critical medications like immunosuppressants where every dose matters.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini